Similar Articles |
|
The Motley Fool August 1, 2007 Ryan Fuhrmann |
Foolish Forecast: CVS Caremark Gets Ready to Rumble CVS Caremark will announce its first combined quarterly results tomorrow. Competitors will be watching to see if the merger of drugstore chain and pharmacy benefit manager is a healthy one. |
The Motley Fool May 8, 2007 Ryan Fuhrmann |
CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results. |
The Motley Fool April 9, 2007 Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note. |
The Motley Fool November 2, 2006 Ryan Fuhrmann |
CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note. |
The Motley Fool August 31, 2011 Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue. |
The Motley Fool June 10, 2004 Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition. |
The Motley Fool October 2, 2011 Shubh Datta |
Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment? |
The Motley Fool September 22, 2006 Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note. |
The Motley Fool January 8, 2007 Matthew Crews |
CVS' Tightrope Walk The drugstore chain's aggressive growth strategy continues to pay off -- for now. Investors, take note. |
The Motley Fool July 5, 2005 Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work. |
The Motley Fool September 26, 2006 Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers? |
The Motley Fool March 26, 2010 Cathy Applefeld Olson |
Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup. |
The Motley Fool June 29, 2006 Ryan Fuhrmann |
Walgreen's Prescription for Growth The drugstore chain continues to roll, even if it is a bit pricey. Great companies rarely trade at bargain-basement levels. But if savvy investors keep a watchful eye, they may find an opportunity to pick up some shares at a fairer price. |
The Motley Fool February 2, 2007 Ryan Fuhrmann |
Uncertain Outlook on CVS Has the retail pharmacy bit off more than it can chew? Investors may soon look back longingly to the day when CVS focused as much on organic, or internal, means to grow its business as it does on acquisitions to buy outside market share. |
The Motley Fool June 10, 2010 Claire Stephanic |
CVS Caremark vs. Walgreen The two go head-to-head in competition for pharmacy customers. |
The Motley Fool September 14, 2006 Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector. |
The Motley Fool October 5, 2007 Timothy M. Otte |
CVS: Consistently Very Solid The drugstore giant scores a consistent sales increase in September, as it begins to capitalize on synergies from its CareMark acquisition. |
The Motley Fool March 22, 2010 Dave Mock |
A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst. |
The Motley Fool February 4, 2008 Timothy M. Otte |
CVS Has Major Mo' Fourth-quarter results cap a stellar year for the drugstore retailer. |
The Motley Fool March 26, 2007 Ryan Fuhrmann |
A Healthy Shade of Walgreen: Fool by Numbers The drugstore chain released second-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool December 19, 2006 Matthew Crews |
Express Scripts' Takeover Battle The pharmacy benefits manager challenges CVS with a higher bid for rival Caremark RX. Investors, stay tuned -- this is far from over. |
The Motley Fool June 2, 2004 Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine? |
The Motley Fool March 26, 2007 Ryan Fuhrmann |
Addicted to Growth at Walgreen Walgreen is a steady grower, but that comes at a price. Investors, take note. |
The Motley Fool June 2, 2011 Dee Gill |
CVS's Improved Performance Begins to Drown Out the Dump-Caremark Chants Is the prognosis for CVS looking up? |
The Motley Fool July 14, 2008 Rick Aristotle Munarriz |
4 Stocks That Took a Hike These stocks recently raised their dividends: CVS Caremark... Paychex... Walgreen... Cummins... |
The Motley Fool October 8, 2011 Shubh Datta |
Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide. |
The Motley Fool July 27, 2004 Brian Gorman |
Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans. |
The Motley Fool July 6, 2007 Mike Cianciolo |
Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note. |
The Motley Fool July 6, 2007 Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers. |
The Motley Fool July 6, 2004 Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. |
The Motley Fool June 11, 2007 Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note. |
The Motley Fool July 6, 2004 Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%. |
The Motley Fool July 6, 2007 Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's... |
The Motley Fool March 9, 2004 Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers. |
The Motley Fool May 2, 2008 Timothy M. Otte |
CVS Caremark and the Snickers Factor The soft economy has hit some retail sectors hard. But there are still pockets of life, and CVS Caremark is one of the companies leading the way. |
The Motley Fool January 7, 2010 Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition. |
The Motley Fool November 5, 2007 Timothy M. Otte |
CVS Is in the Zone Pharmacy giant CVS grew EPS by 36% in the third quarter. The company has been on a roll since its merger with Caremark last year. |
The Motley Fool June 25, 2007 Ryan Fuhrmann |
Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see. |
The Motley Fool June 26, 2007 Ryan Fuhrmann |
Walgreen Sells Convenience Walgreen continues to grow market share, with little sign of slowing down. |
The Motley Fool January 5, 2007 Matthew Crews |
Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve. |
The Motley Fool June 30, 2011 David Williamson |
Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split. |
BusinessWeek September 19, 2005 Gene G. Marcial |
CVS' Ever-Expanding Aisles According to analysts, the aging population and improving pipeline of new drugs will help the retail pharmacy achieve its goal of 15% overall long-term earnings growth. Investors, take note. |
The Motley Fool January 3, 2005 Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool February 14, 2005 Brian Gorman |
GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision. |
The Motley Fool February 2, 2005 Alyce Lomax |
CVS's Shot in the Arm Buying the Eckerd drugstore chain from J.C. Penney was apparently a good move for CVS. It continues to benefit from the purchase, reporting positive earnings and beating analysts' expectations by a penny. |
The Motley Fool June 14, 2010 Jennifer Schonberger |
The S&P 500's Biggest Movers Gannett was among the companies making a move up. |
The Motley Fool August 16, 2007 Lawrence Rothman |
Longs' Prescription for Success Longs Drug Stores may be small, but it excels in its regional niche. Operating primarily on the West Coast, second-quarter results show a company with lots of room for growth. |
The Motley Fool April 29, 2010 Brian Orelli |
A Prescription to Investigate Further Let's not worry just yet about Medco's margins. |
The Motley Fool November 10, 2004 Dave Marino-Nachison |
Investors Adjusting to Larger CVS The drugstore company's chains have done nothing but rise since the Eckerd buy. Investors have pulled the company's shares steadily upward since the merger closed. |
The Motley Fool June 2, 2011 Seth Jayson |
One Reason the Street Should Love CVS Caremark's Earnings With both 12-month and quarterly CCC running better than average, CVS Caremark gets high marks in this cash-conversion checkup. |